Pharmafile Logo
Pharmafocus logo
Advanced Search

PTC Therapeutics

Showing 13 posts of 13 posts found.

Roche building

Roche’s Evrysdi drug for SMA shown to significantly increase survival

April 15, 2021
PTC Therapeutics, Roche, pharma, pharma news, spinal muscular atrophy

Roche’s Evrysdi therapy for the treatment of children with type 1 spinal muscular atrophy (SMA) has been shown to increase …

News
Roche building

Roche’s SMA treatment Evrysdi approved by European Commission

March 30, 2021
Manufacturing and Production EMA, European Commission, PTC Therapeutics, Roche, sma, spinal muscular atrophy

The European Commission has granted marketing authorisation to Roche and PTC Therapeutics’ Evrysdi, for the treatment of patients aged 2 …

News

Roche and PTC’s SMA treatment shows positive trial results

March 16, 2021
Manufacturing and Production PTC, PTC Therapeutics, Roche, sma, spinal muscular atrophy

Roche and PTC Therapeutics’s Evrysdi treatment for children and adults with Type 2 or Type 3 spinal muscular atrophy (SMA) …

News
ptc

PTC Therapeutics’ results in SMA has Biogen nervous

June 19, 2018
Manufacturing and Production, Research and Development Biogen, PTC Therapeutics, biotech, drugs, pharma, pharmaceutical

Biogen currently has the only product on the market approved to treat spinal muscular atrophy (SMA), in Spinraza, and that …

News
money_packets

Duchenne drug poised to cost $35,000 but with major catch

May 9, 2017
Manufacturing and Production, Sales and Marketing Duchenne Muscular Dystrophy, PTC Therapeutics, marathon

For those that have not followed the story, Emflaza was successfully taken through the FDA regulatory process by Marathon as …

News
lab

NICE recommends PTC Therapeutics Duchenne muscular dystrophy treatment

July 20, 2016
Research and Development, Sales and Marketing Duchenne Muscular Dystrophy, PTC Therapeutics

PTC Therapeutics has announced that the National Institute for Health and Care Excellence has issued final guidance recommending Translarna (ataluren) …

News

Nice extends price-negotiation talks for PTC’ muscle wasting drug

May 4, 2016
Research and Development, Sales and Marketing Duchenne Muscular Dystrophy, NICE, PTC Therapeutics, Translarna, market access, regulation

UK regulators have extended the cost negotiation talks with PTC Therapeutics (Nasdaq: PTCT) by a week for the drug to …

News
drugs1

NICE recommends PTC Therapeutics’ Translarna to treat Duchenne muscular dystrophy

April 18, 2016
Sales and Marketing DMD, Duchenne Muscular Dystrophy, NICE, PTC Therapeutics, Translarna, regulation

Shares in drug maker PTC Therapeutics (Nasdaq: PTCT) jumped after the National Institute for Health and Care Excellence (NICE) backed …

News
ptc_therapeutics_logo

PTC Therapeutics to cut jobs after FDA rejects Duchenne drug

March 24, 2016
Manufacturing and Production Duchenne Muscular Dystrophy, PTC Therapeutics

PTC Therapeutics has announced plans to reduce its operating expenses that will see it cut almost a fifth of its …

News

PTC Therapeutics to file new Phase III data for genetic muscle disorder drug in Canada

March 15, 2016
Manufacturing and Production, Research and Development Canada, PTC Therapeutics, Translarna, nonsense mutation Duchenne muscular dystrophy, phase III

PTC Therapeutics (Nasdaq: PTCT) said it does not expect the Canadian regulators to review its trial drug to treat a …

News
robert_j

PTC Therapeutics makes series of changes

January 27, 2014
Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing PTC Therapeutics

Biopharma firm PTC Therapeutics has expanded its senior management team with a raft of appointments. Robert Spiegel (pictured) becomes its …

Appointment
Roche picture

Roche inks $490 million deal with PTC Therapeutics

November 30, 2011
Research and Development, Sales and Marketing PTC Therapeutics, Roche

Roche has signed a $490 million deal with specialist biotech firm PTC Therapeutics. Roche is paying PTC $30 million upfront …

News

AstraZeneca signs cancer drug discovery collaboration

June 30, 2011
Research and Development AstraZeneca, PTC Therapeutics

AstraZeneca has signed a deal with PTC Therapeutics to use the company’s proprietary drug discovery platform to discover new cancer …

News

Latest content

Sanofi shares results for phase 3 LUNA 3 trial in immune thrombocytopenia

April 23, 2024

FDA approves ImmunityBio’s Anktiva bladder cancer treatment

April 23, 2024

EC approves Pfizer’s Emblaveo for multidrug-resistant infection treatment

April 22, 2024

Neurolentech and Kaerus Bioscience enter partnership for research on neurodevelopmental disorder

April 22, 2024

Ardena announces €20m expansion following first GMP approval

April 19, 2024